Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100S6X1
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥4.4bn2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥444m2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥589m2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥537m2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥562m2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥562m2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥15.8bnat 2023-09-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥16.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-12.092023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.982023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio61.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥738m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥643m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-09-30−¥17m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥955m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30¥293m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 365
ItemContextValueUnit
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember3688000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember724000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember4000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember4417000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration4417000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember3688000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember724000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember4000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember4417000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration4417000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember955000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember-643000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember-17000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember293000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-738000000JPY
Operating incomeCurrentYTDDuration-444000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)近畿財務局長
Filing date cover pageFilingDateInstant2023-11-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第78期第３四半期（自　2023年７月１日　至　2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)大幸薬品株式会社
Company name in english cover pageFilingDateInstantTAIKO PHARMACEUTICAL CO.,LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　柴田　高
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府吹田市内本町三丁目34番14号（同所は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当事項はありません。
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当事項はありません。
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市西区西本町一丁目４番１号　オリックス本町ビル16階
Telephone number nearest place of contact cover pageFilingDateInstant０６－４３９１－１１２３
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経理部長　中條　亨
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE22560
Fund codeFilingDateInstant－
Security codeFilingDateInstant45740
Filer name in japaneseFilingDateInstant
Original text (Japanese)大幸薬品株式会社
Filer name in englishFilingDateInstantTAIKO PHARMACEUTICAL CO.,LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass